Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CFD | P00746 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17023502 | 0.91 | GAA (0.47) | GAACFDLMNACNR2SMN1; SMN2 | |
| SCHEMBL17024952 | 0.88 | PLA2G4A (0.45) | GAACFDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12479921 | 0.84 | CNR1 (0.47) | GAACFDLMNACNR1CNR2 | |
| SCHEMBL17032686 | 0.83 | SMN1; SMN2 (0.47) | GAALMNACNR1CNR2SMN1; SMN2 | |
| SCHEMBL17023365 | 0.83 | SMN1; SMN2 (0.40) | GAACFDLMNACNR1CNR2 | |
| SCHEMBL17023368 | 0.82 | KRAS (0.41) | GAALMNACNR1CNR2SMN1; SMN2 | |
| SCHEMBL29869185 | 0.82 | KRAS (0.41) | GAALMNACNR1CNR2SMN1; SMN2 | |
| SCHEMBL4342789 | 0.81 | CPT2 (0.44) | GAALMNACNR2ALDH1A1CREBBP | |
| SCHEMBL19478892 | 0.80 | CNR2 (0.47) | GAACFDLMNACNR1CNR2 | |
| SCHEMBL17023509 | 0.79 | GAA (0.58) | GAALMNASMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10660876-B2 | Amino compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10189869-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180177761-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | GAA 4693/4885CFD 1/4885LMNA 1952/4885 |
| US-10189869-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | GAA 4693/4885CFD 1/4885LMNA 1952/4885 |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | CFD, TFPI, TFPI2 | GAA 3734/4885CFD 1/4885LMNA 1884/4885 |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | CFD, C9, CFH | GAA 3663/4885CFD 1/4885LMNA 1726/4885 |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | GAA 3877/4885CFD 1/4885LMNA 2178/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | GAA 4693/4885CFD 1/4885LMNA 1952/4885 |
| US-10660876-B2 | Amino compounds for treatment of medical disorders | CFD, CFH, F12 | GAA 3648/4885CFD 1/4885LMNA 1013/4885 |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | GAA 4379/4885CFD 1/4885LMNA 2004/4885 |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | GAA 4379/4885CFD 1/4885LMNA 2004/4885 |
| US-20180177761-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, CFH, F12 | GAA 3648/4885CFD 1/4885LMNA 1013/4885 |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | GAA 4693/4885CFD 1/4885LMNA 1952/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | GAA 3663/4885CFD 1/4885LMNA 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.